Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody targeting a pyroglutamate amyloid beta (Abeta) epitope at the N-terminus. It shows promise for research in early Alzheimers disease [1] [2].
CAS Number:
[1931944-80-7]
* VAT and and shipping costs not included. Errors and price changes excepted
